Drug Trial Radar · NCT00816972
Desloratadine With Oxybutynin for the Treatment of Seasonal Allergic Rhinitis and Post-Nasal Drip (Study P04258)(COMPLETED)
Last checked: Nov 20, 2026Latest source record: Feb 16, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
540
Actual
Start
Apr 2005
Primary completion
Jun 2005
Study completion Jun 2005
Sponsor
- Lead sponsor
- Organon and CoIndustry
- Sponsor type
- Industry
- First posted
- Jan 6, 2009
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a 1-week study of desloratadine (DL) plus oxybutynin (OXY) at two dose levels in the treatment of post-nasal drip in participants with seasonal allergic rhinitis. Participants received either desloratadine twice a day, oxybutynin twice a day, desloratadine plus lower-dose oxybutynin twice a day, desloratadine plus higher-dose oxybutynin twice a day, or placebo for 7 days.
Conditions
- Post-nasal Drip
- Seasonal Allergic Rhinitis
- Rhinorrhea
Interventions
Desloratadine 2.5 mgDrug
Desloratadine 2.5 mg BID
Oxybutynin 2.5 mgDrug
Oxybutynin 2.5 mg BID
Placebo for Desloratadine 2.5 mgDrug
Placebo BID
Placebo for Oxybutynin 2.5 mgDrug
Placebo BID
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in mean daily AM/PM Prior post-nasal drip scores averaged over the entire treatment periodTime frame: Days 1 to 7 +/- 2 days
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.